Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012

European Neuropsychopharmacology

Volumn 26, Issue 3, 2016, Pages 411-419

  Bachmann, Christian J ^a   Aagaard, Lise ^b   Burcu, Mehmet ^c   Glaeske, Gerd ^d   Kalverdijk, Luuk J ^e   Petersen, Irene ^f   Schuiling Veninga, Catharina C M ^g   Wijlaars, Linda ^f,h   Zito, Julie M ^c,i   Hoffmann, Falk ^j  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF BREMEN   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF OLDENBURG   (Germany)

more..

Author keywords

Adolescent; Antidepressant agents; Black box warning; Child; Multinational; Prevalence trends

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH INSURANCE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DENMARK; DRUG USE; FEMALE; GERMANY; HUMAN; JUVENILE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; AGE DISTRIBUTION; CLINICAL PRACTICE; DEPRESSION; EUROPE; INFANT; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TRENDS; YOUNG ADULT;

ADOLESCENT; AGE DISTRIBUTION; ANTIDEPRESSIVE AGENTS; CHILD, PRESCHOOL; DEPRESSION; EUROPE; FEMALE; HUMANS; INFANT; MALE; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84962010078     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.02.001     Document Type: Article

References (52)

1. Acquaviva E., Legleye S., Auleley G.R., Deligne J., Carel D., Falissard B.B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009, 9:72.
2. Bachmann C.J., Lempp T., Glaeske G., Hoffmann F. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch. Arzteblatt Int. 2014, 111:25-34.
3. Bergen H., Hawton K., Murphy E., Cooper J., Kapur N., Stalker C., Waters K. Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds. Br. J. Clin. Pharmacol. 2009, 68:618-629.
4. Blak B.T., Thompson M., Dattani H., Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform. Prim. Care 2011, 19:251-255.
5. Breland D.J., McCarty C.A., Zhou C., McCauley E., Rockhill C., Katon W., Richardson L.P. Determinants of mental health service use among depressed adolescents. Gen. Hosp. Psychiatry 2014, 36:296-301.
6. Brent D.A. Antidepressants and pediatric depression - the risk of doing nothing. N. Engl. J. Med. 2004, 351:1598-1601.
7. Busch S.H., Barry C.L. Pediatric antidepressant use after the black-box warning. Health Aff. 2009, 28:724-733.
8. Byck G.R. A comparison of the socioeconomic and health status characteristics of uninsured, state children[U+05F3]s health insurance program-eligible children in the united states with those of other groups of insured children: implications for policy. Pediatrics 2000, 106:14-21.
9. Correll C.U., Gerhard T., Olfson M. Prescribing of psychotropic medications to children and adolescents: quo vadis?. World Psychiatry 2013, 12:127-128.
10. Dalsgaard S., Nielsen H.S., Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study. J. Child Adolesc. Psychopharmacol. 2013, 23:432-439.
11. Dörks M., Langner I., Dittmann U., Timmer A., Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in germany: results from a large population-based cohort study. Eur. Child Adolesc. Psychiatry 2013, 22:511-518.
12. Fontanella C.A., Bridge J.A., Marcus S.C., Campo J.V. Factors associated with antidepressant adherence for medicaid-enrolled children and adolescents. Ann. Pharmacother. 2011, 45:898-909.
13. Fontanella C.A., Warner L.A., Phillips G.S., Bridge J.A., Campo J.V. Trends in psychotropic polypharmacy among youths enrolled in Ohio medicaid, 2002-2008. Psychiatr. Serv. 2014, 65:1332-1340.
14. Friedman R.A. Antidepressants[U+05F3] black-box warning - 10 years later. N. Engl. J. Med. 2014, 371:1666-1668.
15. Hazell, P., Mirzaie, M., 2013. Tricyclic drugs for depression in children and adolescents. The Cochrane Database of Systematic Reviews, CD002317.
16. Health and Social Care Information Centre, 2015. Prescriptions dispensed in the community. Statistics for England, 2004-2014. 〈http://www.hscic.gov.uk/catalogue/PUB17644/pres-disp-com-eng-2004-14-rep.pdf〉 (accessed 12.02.2016).
17. Hoffmann F., Bachmann C.J. Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds. Bundesgesundheitsblatt Gesundh. Gesundh. 2014, 57:455-463.
18. Hoffmann F., Glaeske G., Bachmann C.J. Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. Pharmacoepidemiol. Drug Saf. 2014, 23:1268-1272.
19. Hölling H., Schlack R., Petermann F., Ravens-Sieberer U., Mauz E. Psychopathological problems and psychosocial impairment in children and adolescents aged 3-17 years in the German population: prevalence and time trends at two measurement points (2003-2006 and 2009-2012): results of the KiGGS study: first follow-up (KiGGS wave 1). Bundesgesundheitsblatt Gesundh. Gesundh. 2014, 57:807-819.
20. Horsfall L., Walters K., Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol. Drug Saf. 2013, 22:64-69.
21. Kalverdijk L.J., Tobi H., van den Berg P.B., Buiskool J., Wagenaar L., Minderaa R.B., de Jong-van den Berg L.T. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr. Serv. 2008, 59:554-560.
22. Katz L.Y., Kozyrskyj A.L., Prior H.J., Enns M.W., Cox B.J., Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. Can. Med. Assoc. J. 2008, 178:1005-1011.
23. Kesselheim A.S., Mello M.M., Studdert D.M. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011, 8:e1000431.
24. Kessler R.C., Avenevoli S., Green J., Gruber M.J., Guyer M., He Y., Jin R., Kaufman J., Sampson N.A., Zaslavsky A.M. National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessments. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:386-399.
25. Kondro W., Sibbald B. Drug company experts advised staff to withhold data about SSRI use in children. Can. Med. Assoc. J 2004, 170:783.
26. Kurian B.T., Ray W.A., Arbogast P.G., Fuchs D.C., Dudley J.A., Cooper W.O. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch. Pediatr. Adolesc. Med. 2007, 161:690-696.
27. Larkin I., Ang D., Avorn J., Kesselheim A.S. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Aff. 2014, 33:1014-1023.
28. Lee E., Teschemaker A., Johann-Liang R., Bazemore G., Yoon M., Shim K., Daniel M., Pittman J., Wutoh A. Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol. Drug Saf. 2012, 21:137-144.
29. Maguire A., Blak B.T., Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol. Drug Saf. 2009, 18:76-83.
30. Meng X., D'Arcy C., Tempier R. Long-term trend in pediatric antidepressant use, 1983-2007: a population-based study. Can. J. Psychiatry 2014, 59:89-97.
31. Merikangas K.R., Nakamura E.F., Kessler R.C. Epidemiology of mental disorders in children and adolescents. Dialogues Clin. Neurosci. 2009, 11:7-20.
32. NHS National Information Centre, 2011. Prescription compliance: a review of the proportion of prescriptions dispensed. 〈〉 (accessed 12.02.16). http://www.hscic.gov.uk/catalogue/PUB01500/pres-comp-rev-prop-pres-disp-rep.pdf.
33. Olfson M., Blanco C., Liu S.M., Wang S., Correll C.U. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch. Gen. Psychiatry 2012, 69:1247-1256.
34. Olfson M., Marcus S.C., Druss B.G. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch. Gen. Psychiatry 2008, 65:94-101.
35. Pottegard A., Zoega H., Hallas J., Damkier P. Use of SSRIs among Danish children: a nationwide study. Eur. Child Adolesc. Psychiatry 2014, 23:1211-1218.
36. Rapoport J.L. Pediatric psychopharmacology: too much or too little?. World Psychiatry 2013, 12:118-123.
37. Ronsley R., Scott D., Warburton W.P., Hamdi R.D., Louie D.C., Davidson J., Panagiotopoulos C. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can. J. Psychiatry 2013, 58:361-369.
38. Safer D.J., Rajakannan T., Burcu M., Zito J.M. Trends in subthreshold psychiatric diagnoses for youth in community treatment. JAMA Psychiatry 2015, 72:75-83.
39. Schomerus G., Matschinger H., Baumeister S.E., Mojtabai R., Angermeyer M.C. Public attitudes towards psychiatric medication: a comparison between United States and Germany. World Psychiatry 2014, 13:320-321.
40. Sellers R., Maughan B., Pickles A., Thapar A., Collishaw S. Trends in parent- and teacher-rated emotional, conduct and adhd problems and their impact in prepubertal children in Great Britain: 1999-2008. J. Child Psychol. Psychiatry 2015, 56:49-57.
41. Steinhausen H.C. A European perspective on paedo-psychiatric pharmacoepidemiology. World Psychiatry 2013, 12:131-132.
42. Steinhausen H.C. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur. Child Adolesc. Psychiatry 2015, 24:635-640.
43. Steinhausen H.C., Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr. Scand. 2014, 129:221-231.
44. Taylor E. Pediatric psychopharmacology: too much and too little. World Psychiatry 2013, 12:124-125.
45. The Henry J Kaiser Family Foundation, 2015. Medicaid and CHIP income eligibility limits for children as a percent of the federal poverty level. (accessed 12.02.2016). http://kff.org/medicaid/state-indicator/medicaidchip-upper-income-eligibility-limits-for-children/.
46. Valluri S., Zito J.M., Safer D.J., Zuckerman I.H., Mullins C.D., Korelitz J.J. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med. Care 2010, 48:947-954.
47. Visser S.T., Schuiling-Veninga C.C., Bos J.H., de Jong-van den Berg L.T., Postma M.J. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev. Pharmacoecon. Outcomes Res. 2013, 13:285-292.
48. von Soest T., Bramness J.G., Pedersen W., Wichstrom L. The relationship between socio-economic status and antidepressant prescription: a longitudinal survey and register study of young adults. Epidemiol. Psychiatr. Sci. 2012, 21:87-95.
49. Wijlaars L.P., Nazareth I., Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 2012, 7:e33181.
50. Wittkampf L.C., Smeets H.M., Knol M.J., Geerlings M.I., Braam A.W., De Wit N.J. Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc. Psychiatry Psychiatr. Epidemiol. 2010, 45:819-826.
51. Zito J.M., Tobi H., de Jong-van den Berg L.T., Fegert J.M., Safer D.J., Janhsen K., Hansen D.G., Gardner J.F., Glaeske G. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol. Drug Saf. 2006, 15:793-798.
52. Zoega H., Baldursson G., Hrafnkelsson B., Almarsdottir A.B., Valdimarsdottir U., Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J. Child Adolesc. Psychopharmacol. 2009, 19:757-764.